| Hazard Information | Back Directory | [Description]
ATL802 is an adenosine A2B Receptor antagonist. After IR, ATL802 treatment significantly improved lung function (increased pulmonary compliance and reduced airway resistance and pulmonary artery pressure) and significantly attenuated proinflammatory cytokine production, neutrophil infiltration, vascular permeability, and edema. ATL802 also significantly improved the function of DCD lungs after EVLP (increased compliance and reduced pulmonary artery pressure). After HR, A549 cells exhibited robust production of interleukin (IL)-8, a potent neutrophil chemokine, which was significantly attenuated by ATL802. | [Uses]
ATL-802 is a potent adenosine A2B receptor antagonist. ATL-802 is promising for research of diabetes[1]. | [References]
[1] LINDEN, Joel, et al. Reducing diabetes in patients receiving HMG-CoA reductase inhibitors (statins) comprising administering adenosine receptor antagonists or CD73 antagonists. WO2014153424 A1. 2014 September 25. |
|
|